PDF(547 KB)
Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy
LIANG Ming-Juan, QIU Wei-Feng, ZHANG Jing-Wen, LI Xue-Ping, SHI Gang-An, ZHAI Qiong-Xiang, ZHANG Yu-Xin, CHEN Zhi-Hong
Chinese Journal of Contemporary Pediatrics ›› 2022, Vol. 24 ›› Issue (3) : 285-289.
PDF(547 KB)
PDF(547 KB)
Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy
Objective To study the efficacy and safety of domestic generic levetiracetam in replacement of brand-name levetiracetam in the treatment of children with epilepsy. Methods A retrospective analysis was performed on the medical data of 154 children with epilepsy who received domestic generic levetiracetam in the inpatient or outpatient service of Guangdong Provincial People's Hospital from May 2019 to December 2020. Domestic generic levetiracetam and brand-name levetiracetam were compared in terms of efficacy and safety. Results For these 154 children, the epilepsy control rate was 77.3% (119/154) at baseline. At 6 months after switching to domestic generic levetiracetam, the epilepsy control rate reached 83.8% (129/154), which showed a significant increase (P<0.05). There was no significant change in the frequency of seizures from baseline to 6 months after switching (P>0.05). The incidence of refractory epilepsy in children with no response after switching treatment was significantly higher than that in children with response (P<0.05). Before switching, only 1 child (0.6%) experienced somnolence, while after switching, 3 children (1.9%) experienced mild adverse drug reactions, including dizziness, somnolence, irritability, and bad temper. Conclusions Switching from brand-name to generic levetiracetam is safe and effective and holds promise for clinical application, but more prospective randomized controlled trials are required in future.
Epilepsy / Levetiracetam / Generic drug / Brand-name drug / Switching treatment / Child
1 中国抗癫痫协会. 临床诊疗指南—癫痫病分册[M]. 2版. 北京: 人民卫生出版社, 2015.
2 Abou-Khalil B. Levetiracetam in the treatment of epilepsy[J]. Neuropsychiatr Dis Treat, 2008, 4(3): 507-523. PMID: 18830435. PMCID: PMC2526377. DOI: 10.2147/ndt.s2937.
3 Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments[J]. Lancet Neurol, 2007, 6(5): 465-468. PMID: 17434101. DOI: 10.1016/S1474-4422(07)70105-9.
4 Perucca E, Albani F, Capovilla G, et al. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs[J]. Epilepsia, 2006, 47 Suppl 5: 16-20. PMID: 17239100. DOI: 10.1111/j.1528-1167.2006.00871.x.
5 Hensler K, Uhlmann C, Porschen T, et al. Generic substitution of antiepileptic drugs—a survey of patients' perspectives in Germany and other German-speaking countries[J]. Epilepsy Behav, 2013, 27(1): 135-139. PMID: 23416284. DOI: 10.1016/j.yebeh.2012.12.029.
6 国务院办公厅. 国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知国办发〔2019〕2号[J]. 中国制药信息, 2019(3): 7-10.
7 Markoula S, Chatzistefanidis D, Gatzonis S, et al. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting[J]. Seizure, 2017, 48: 1-6. PMID: 28363098. DOI: 10.1016/j.seizure.2017.03.012.
8 Gha-Hyun L, Dae SJ. Brand name to generic substitution of levetiracetam in patients with epilepsy[J]. Seizure, 2018, 60: 127-131. PMID: 29960217. DOI: 10.1016/j.seizure.2018.06.020.
9 王艳, 赵新利, 谭军, 等. 左乙拉西坦佐治儿童难治性癫痫的疗效[J]. 新乡医学院学报, 2013, 30(12): 972-974.
10 Chaluvadi S, Chiang S, Tran L, et al. Clinical experience with generic levetiracetam in people with epilepsy[J]. Epilepsia, 2011, 52(4): 810-815. PMID: 21426334. PMCID: PMC4500114. DOI: 10.1111/j.1528-1167.2011.03025.x.
11 Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures[J]. Ann Pharmacother, 2011, 45(5): e27. PMID: 21521860. DOI: 10.1345/aph.1P765.
12 Lang JD, Kostev K, Onugoren MD, et al. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany[J]. Ann Neurol, 2018, 84(6): 918-925. PMID: 30298621. DOI: 10.1002/ana.25353.
13 Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs[J]. J Pediatr Pharmacol Ther, 2010, 15(2): 81-93. PMID: 22477799. PMCID: PMC3018179.
14 Privitera MD, Welty TE, Gidal BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial[J]. Lancet Neurol, 2016, 15(4): 365-372. PMID: 26875743. DOI: 10.1016/S1474-4422(16)00014-4.
15 Vossler DG, Anderson GD, Bainbridge J. AES position statement on generic substitution of antiepileptic drugs[J]. Epilepsy Curr, 2016, 16(3): 209-211. PMID: 27330454. PMCID: PMC4913860. DOI: 10.5698/1535-7511-16.3.209.
16 Medicines and Healthcare products Regulatory Agency. Antiepileptic drugs: new advice on switching between different manufacturers' products for a particular drug[EB/OL]. (2014-12-11)[2020-10-07]. https://www.gov.uk/drug-safety-update/antiepileptic-drugs-new-advice-on-switching-between-different-manufacturers-products-for-a-particular-drug.
17 Bosak M, S?owik A, Turaj W. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy[J]. Drug Des Devel Ther, 2017, 11: 2287-2291. PMID: 28814836. PMCID: PMC5546726. DOI: 10.2147/DDDT.S138270.
18 Reimers A, Olsson P, Nilsson J, et al. Impact of generic substitution on levetiracetam serum concentration—a prospective study in an outpatient setting[J]. Epilepsy Res, 2017, 134: 54-61. PMID: 28595756. DOI: 10.1016/j.eplepsyres.2017.04.017.
19 Trimboli M, Russo E, Mumoli L, et al. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study[J]. Eur J Neurol, 2018, 25(4): 666-671. PMID: 29322654. DOI: 10.1111/ene.13568.
20 Vari MS, Pinto F, Mencaroni E, et al. Safety of overnight switch from brand-name to generic levetiracetam[J]. Clin Drug Investig, 2016, 36(1): 87-91. PMID: 26507620. DOI: 10.1007/s40261-015-0351-1.
21 Fanella M, Morano A, Fattouch J, et al. Switch from originator to equivalent drug in the era of generic antiepileptic drugs: study of Keppra versus Epitiram clinical equivalence[J]. Clin Neuropharmacol, 2017, 40(6): 239-242. PMID: 28976412. DOI: 10.1097/WNF.0000000000000250.
22 Peterson GM. Generic substitution of antiepileptics: need for a balanced view[J]. CNS Spectr, 2011, 16(8): 169-175. PMID: 24725557. DOI: 10.1017/S109285291200034X.
